Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (HEBEI CHANGSHAN BIOCHEMICAL PHA) Aktie

Hebei Changshan Biochemical Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, marketing, and sale of drugs for cardiovascular, cerebrovascular, diabetes, and cancer in China and internationally. It offers heparin sodium, calcium, and lithium, as well as heparinoid, LMW heparins, and sodium hyaluronate; dalteparin sodium, enoxaparin sodium, nadroparin calcium, and heparin sodium injections, as well as sildenafil citrate tablet; and albenatide. The company is also involved in technology development; consulting; transfer services; investment and management of medical service projects; wholesale and retail of pharmaceuticals; and diagnosis services. It exports its products to the United States, Germany, France, Italy, Spain, South Korea, Japan, Russia, India, the Philippines, and other countries. The company was founded in 1992 and is based in Shijiazhuang, China.